# Efficacy and Safety/Tolerability of Grass MATA MPL

> **NCT00414141** · PHASE3 · COMPLETED · sponsor: **Allergy Therapeutics** · enrollment: 1028 (actual)

## Conditions studied

- Type I Hypersensitivity

## Interventions

- **BIOLOGICAL:** Grass MATA MPL
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00414141
- **Lead sponsor:** Allergy Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2007-08
- **Final completion:** 2007-11
- **Target enrollment:** 1028 (ACTUAL)
- **Last updated:** 2010-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00414141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00414141, "Efficacy and Safety/Tolerability of Grass MATA MPL". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00414141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*